Percutaneous Electrical Nerve Stimulation (PENS) and Percutaneous Neuromodulation Therapy (PNT) Policy
Policy governing coverage determinations for PENS and PNT for chronic pain across Blue Cross & Blue Shield of Rhode Island products, with separate stances for BlueCHiP for Medicare and Commercial products, coding guidance, and prior authorization information.
No material changes
Coverage Summary & Medical Necessity
This policy governs coverage determinations for Percutaneous Electrical Nerve Stimulation (PENS) and Percutaneous Neuromodulation Therapy (PNT) for chronic pain across Blue Cross & Blue Shield of Rhode Island products. Effective date: 10/02/2018; Last review: 10/02/2018. Coverage stance is mixed: for BlueCHiP for Medicare PENS/PNT are covered with specific medical necessity criteria, whereas for Commercial products PENS/PNT are considered not medically necessary because the evidence is insufficient to determine effects on health outcomes.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.